Campuzano, RaquelMostaza, José MaríaBarrios, VivencioEgocheaga-Cabello, IsabelGómez-Cerezo, Jorge FranciscoPallarés-Carratalá, VicenteMartínez-López, IciarCastellanos, María del MarHernández-Subirá, IgnacioMorant-Talamante, NuriaParrondo, JavierArigita-Lastra, LuisGámez, José M.2025-04-212025-04-212025-03-28Campuzano R, Mostaza JM, Barrios V, Egocheaga-Cabello I, Gómez-Cerezo JF, Pallarés-Carratalá V, Martínez-López I, Castellanos M, Hernández-Subirá I, Morant-Talamante N, Parrondo J, Arigita-Lastra L, Gámez JM. Assessing LDL-C levels and lipid-modifying therapies in a real-world cohort of patients with atherosclerotic cardiovascular disease: the REALITY study. J Clin Med. 2025 Mar 28;14(7):2340.2077-0383http://hdl.handle.net/2183/41793[Abstract] Background and Objectives: Patients with atherosclerotic cardiovascular disease (ASCVD) remain at high risk of recurrent events. REALITY aims to analyse the actual levels of low-density lipoprotein cholesterol (LDL-C), the modalities of lipid-lowering therapies (LLT) used, and ASCVD patient outcomes in a real-world setting in Spain. Methods: REALITY is a retrospective observational study conducted using a healthcare database of 1.8 million patients representative of the Spanish population. The study included 26,976 patients with new or recurrent ASCVD events recruited from 2017 to 2019 and followed up for two years. Results: Management of ASCVD involved the utilisation of high-intensity (53%) or very high-intensity (36%) LLT. After two years, a decrease in total cholesterol (from 228.7 to 176.7 mg/dL), LDL-C (from 126.4 to 99.0 mg/dL), and triglycerides (from 216.7 to 163.7 mg/dL), accompanied by a moderate increase in HDL-C levels was observed. However, LDL-C goals of ESC/EAS guidelines were only reached by a minority of patients. Less than 15% of ASCVD patients achieved their LDL-C goals of <70, as stated in contemporary guidelines (3% if the present <55 mg/dL threshold in the ESC/EAS guidelines is considered). During the follow-up period, 9% of ASCVD patients died and 25% experienced a new ASCVD event. Conclusions: In the REALITY study, most patients did not achieve their target LDL-C goals despite receiving high- or very high-intensity LLT. Increasing the utilisation of extreme LLT is crucial to reducing recurrent ASCVD events and mitigating these patients' high morbidity and mortality risk.engCreative Commons Attribution 4.0 International License (CC-BY 4.0)http://creativecommons.org/licenses/by/3.0/es/LDL-C levelsAtherosclerotic cardiovascular diseaseLipid-modifying therapiesReal-world datajournal articleopen access10.3390/jcm14072340